Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

Multiple Sclerosis is a condition in which the body’s immune system mistakenly attacks the protective covering of nerve fibers, leading to problems with movement, vision, and feeling. The study uses the medicine Ocrelizumab, which is given as a high‑concentration injection under the skin (subcutaneous) using a small device that can be worn on the body.

The purpose of the study is to see whether the on‑body delivery system can be safely and effectively used by patients or a non‑medical caregiver at home.

Participants will receive the first dose at home during the first week, followed by additional doses around the 24‑week and 48‑week marks. Throughout the study, the occurrence of any problems with the injection, such as redness, swelling, or pain (known as injection reactions), and any issues related to the device itself will be recorded and managed as needed.

The research process

The trial runs in 10 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial training on the on-body delivery system

    Receive instruction on how to attach and operate the on-body delivery system, a device that holds the medication and delivers it under the skin.

    Learn how to check that the device is working correctly and how to record any problems.

  2. Step 2

    Preparation for the first dose (week 1)

    Ensure the device is loaded with the medication ocrelizumab as supplied by the study team.

    Verify that the medication is a solution for injection intended for subcutaneous injection, which means it will be placed just under the skin.

  3. Step 3

    Self‑administration or caregiver administration of week 1 dose

    Administer the dose of ocrelizumab using the on-body delivery system according to the instructions.

    The dose amount is determined by the study protocol and is delivered as a single subcutaneous injection.

  4. Step 4

    Post‑injection monitoring after week 1 dose

    Observe the injection site for any reactions such as redness, swelling, or pain.

    Record any symptoms or device issues and report them according to the study instructions.

  5. Step 5

    Preparation for the second dose (week 24)

    Repeat the device check and loading procedure using the new supply of ocrelizumab.

    Confirm that the device is ready for the subcutaneous injection.

  6. Step 6

    Self‑administration or caregiver administration of week 24 dose

    Administer the second dose of ocrelizumab with the on-body delivery system in the same manner as the first dose.

  7. Step 7

    Post‑injection monitoring after week 24 dose

    Watch for injection reactions or device problems and document any findings.

  8. Step 8

    Preparation for the third dose (week 48)

    Perform the device and medication check again using the final supply of ocrelizumab.

  9. Step 9

    Self‑administration or caregiver administration of week 48 dose

    Give the third dose of ocrelizumab with the on-body delivery system as instructed.

  10. Step 10

    Final monitoring and study completion

    Continue to observe the injection site and overall health for any delayed reactions.

    Complete all required documentation and return the device according to the study guidelines.

Who can join the trial?

6 criteria

  • Age: You must be between 18 and 65 years old when you sign the consent form.
  • Injection method: You must be willing and able to receive the medication using the on‑body delivery system (OBDS). This can be done by you yourself (self‑injection) or by a non‑medical caregiver (a lay caregiver). If you choose self‑injection, your doctor must decide that you have enough movement ability (motor function) and thinking ability (cognitive function) to give the shot safely.
  • Female participants who could become pregnant (childbearing potential): You must agree to either avoid heterosexual intercourse (remain abstinent) or use reliable birth control (contraception) during the treatment period and for six months after the last dose.
  • Female participants who cannot become pregnant (no childbearing potential): You may join the study if you are postmenopausal, meaning your menstrual periods have stopped naturally.
  • Current use of ocrelizumab: You must already be receiving the medication ocrelizumab and have had at least one previous dose of 600 mg given through a vein (IV) or 920 mg given under the skin (SC). The first study dose will be given about six months (± 1 month) after your last pre‑study ocrelizumab dose and cannot be given earlier than five months after that dose.
  • Diagnosis of multiple sclerosis (MS): You must have a confirmed diagnosis of MS based on the most recent version of the McDonald criteria (the guidelines doctors use to diagnose MS).

Who cannot join the trial?

6 criteria

  • Does not have reliable and consistent access to communication such as a telephone or mobile phone.
  • Lives in a location that, in the investigator’s opinion, does not allow timely access to an emergency medical facility.
  • Is pregnant, breastfeeding, or plans to become pregnant during the study or while birth control is required.
  • Has a history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (lab‑made proteins that target specific parts of the immune system).
  • Has sensitivity or intolerance to any ingredient, including excipients (inactive substances used in the medication) of ocrelizumab.
  • Has sensitivity or intolerance to acrylic (a type of plastic material used in the device).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ocrevus (ocrelizumab) is a medication that helps control the immune system in people with multiple sclerosis. It works by targeting specific cells that cause inflammation and damage to the nerves. In this study, participants receive the medication under the skin using a special delivery method, which allows them to give the treatment at home instead of visiting a clinic.

The on-body delivery system (OBDS) is a small, wearable device that holds a high‑concentration form of the medication and automatically delivers it through the skin. It is designed so that patients or a non‑medical caregiver can safely give the injection themselves, making treatment more convenient and reducing the need for frequent clinic visits.

What is already known about the treatment

Ocrevus, Ocrelizumab - It is given as a subcutaneous injection of a liquid solution, using an on‑body delivery device that allows patients or caregivers to administer it at home. Ocrelizumab is an approved drug that is well documented in medical literature for treating multiple sclerosis. It works by binding to a protein called CD20 on certain immune cells, lowering the number of these cells that cause damage in the disease. It is classified as a monoclonal antibody that targets immune system cells.

Investigated diseases

Multiple Sclerosis - Multiple Sclerosis is a condition where the immune system mistakenly attacks the protective covering of nerves in the brain and spinal cord. This damage disrupts the normal flow of nerve signals, causing muscle weakness, numbness, and coordination difficulties. Symptoms often appear in episodes that may improve and then return, or they can become more steady over time. The disease usually begins with mild signs and can slowly involve more parts of the body as the nerve covering continues to be damaged.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-523726-40-00Protocol codeCN46182Estimated enrolment150 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.